VA
BSX icon

Vident Advisory’s Boston Scientific BSX Stock Holding History

Vident Advisory’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.09M Buy
142,771
+50,846
+55% +$2.76M 0.04% 345
2026
Q1 		$5.77M Buy
91,925
+32,245
+54% +$2.58M 0.05% 322
2025
Q4 		$5.69M Sell
59,680
-18,027
-23% -$1.77M 0.05% 297
2025
Q3 		$7.59M Buy
77,707
+22,336
+40% +$2.31M 0.07% 232
2025
Q2 		$5.95M Sell
55,371
-31,147
-36% -$3.15M 0.07% 235
2025
Q1 		$8.73M Sell
86,518
-15,387
-15% -$1.55M 0.13% 154
2024
Q4 		$9.1M Buy
101,905
+8,292
+9% +$730K 0.16% 138
2024
Q3 		$7.84M Buy
93,613
+69,647
+291% +$5.49M 0.2% 99
2024
Q2 		$1.85M Buy
23,966
+4,833
+25% +$354K 0.05% 399
2024
Q1 		$1.31M Buy
19,133
+2,205
+13% +$142K 0.03% 498
2023
Q4 		$979K Buy
16,928
+959
+6% +$51.2K 0.02% 563
2023
Q3 		$843K Buy
+15,969
New +$838K 0.03% 561

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vident Advisory's BSX Position: Q2 2026 in Review

Vident Advisory increased its Boston Scientific (BSX) stake by 55% in Q2 2026, buying an estimated $2.76M and bringing the position to 142,771 shares worth $6.09M. The position accounts for 0.04% of the portfolio, ranked #345.

Vident Advisory first reported a position in BSX in Q3 2023 and has held it in 12 quarters since. The position peaked at $9.1M in Q4 2024. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Vident Advisory held 142,771 shares of Boston Scientific worth $6.09M as of Q2 2026.
  • Vident Advisory bought 50,846 Boston Scientific shares in Q2 2026, an estimated $2.76M.
  • Boston Scientific made up 0.04% of Vident Advisory's portfolio in Q2 2026, its #345 holding.
  • Vident Advisory first reported a position in Boston Scientific in Q3 2023 and has held it in 12 quarters since.
  • Vident Advisory's Boston Scientific position peaked at $9.1M in Q4 2024.
  • 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.